Skip to main content
  • Saved

made a Post

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Source :

https://www.nejm.org/doi/full/10.1056/NEJMoa2116620

The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.


Conclusions: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. (Funded by AstraZeneca and the U.S. government; PROVENT ClinicalTrials.gov number, NCT04625725. opens in new tab.)